Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015

Nov 06, 2015, 16:57 ET from Asterias Biotherapeutics, Inc.

MENLO PARK, Calif., Nov. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating results on Monday, November 9, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Monday, November 9, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate developments.

For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 888-378-0320. For international participants outside the U.S./Canada, the dial-in number is 719-325-2435. For all callers, refer to Conference ID 9794791. To access the live webcast, go to http://asteriasbiotherapeutics.com/events-presentations/.

A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling toll-free (from U.S./Canada) 888-203-1112; international callers dial 719-457-0820. Use the Replay Passcode ID 9794791. Additionally, the archived webcast will be available at http://asteriasbiotherapeutics.com/events-presentations/.  

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. (NYSE MKT: AST) is a leading biotechnology company in the emerging field of regenerative medicine. The Company's proprietary, industry-leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where there is high unmet medical need and inadequate available therapies. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) has demonstrated promise in a Phase 2 study in acute myelogenous leukemia. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic approach to dendritic cell vaccines. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.  

 

SOURCE Asterias Biotherapeutics, Inc.



RELATED LINKS

http://www.asteriasbiotherapeutics.com